Edgewise Therapeutics (NASDAQ:EWTX) is building itself up as a good long-term biotech to hang onto. Especially, when you consider that it was able to report positive results from its phase 2 CANYON ...
The FDA has granted orphan drug designation to CRD-003, an investigational gene therapy for limb-girdle muscular dystrophy ...
- BridgeBio will also share 15-month Phase 2 data and review the Phase 3 clinical trial design of BBP-418, a potential therapeutic for patients with LGMD2I, with initiation of its Phase 3 study ...
A new gene therapy treatment for Duchenne muscular dystrophy (DMD) shows promise of not only arresting the decline of the muscles of those affected by this inherited genetic disease, but perhaps, in ...
Approximately 16 boys with Duchenne Muscular Dystrophy (DMD), including several teenagers, are set to benefit from the drug, ...
"My medicine is making me stronger," 7-year-old Hudson Sanford says after receiving a breakthrough gene therapy for Duchenne Muscular Dystrophy Cara Lynn Shultz is a writer-reporter at PEOPLE. Her ...
Panelists discuss how recent advancements in muscular dystrophy treatment have evolved toward truly disease-modifying therapies using gene replacement, antisense oligonucleotides, and gene transfer ...
One of those things is the CureDuchenne clinic in Denton. It provides care to underserved and uninsured people with Duchenne.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback